Angiogenesis and non-small cell lung cancer

被引:95
|
作者
Cox, G
Jones, JL
Walker, RA
Steward, WP
O'Byrne, KJ
机构
[1] Leicester Royal Infirm, Univ Dept Med Oncol, Leicester LE1 5WW, Leics, England
[2] Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England
[3] Glenfield Gen Hosp, Dept Pathol, Leicester LE3 9QP, Leics, England
关键词
angiogenesis; matrix metalloproteinases; growth factors; apoptosis; non-small cell lung cancer;
D O I
10.1016/S0169-5002(99)00096-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer. Angiogenesis is controlled by a complex interaction between growth and apoptotic factors, proteases and adhesion molecules. The angiogenic process may prove a target for novel therapies such as matrix metalloproteinase inhibitors, growth factor antisense RNA, growth factor. receptor antagonists and naturally occurring antiangiogenic peptides. These agents may be used alone ol in combination with traditional chemotherapy, radiotherapy and surgery. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:81 / 100
页数:20
相关论文
共 50 条
  • [41] Mobocertinib in non-small cell lung cancer
    Liu, Shengwu
    Lowder, Kristen E.
    DRUGS OF TODAY, 2022, 58 (11) : 523 - 530
  • [42] Cetuximab in non-small cell lung cancer
    Ademuyiwa, Foluso O.
    Hanna, Nasser
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (01) : 107 - 113
  • [43] AEG-1 mRNA expression in non-small cell lung cancer is associated with increased tumor angiogenesis
    Ma, Zhihong
    Chen, Yingrong
    Dong, Shunli
    Xu, Xuting
    Liu, Jin
    Song, Pengtao
    Yu, Caihua
    Dai, Licheng
    PATHOLOGY RESEARCH AND PRACTICE, 2017, 213 (10) : 1257 - 1263
  • [44] Ifosfamide in non-small cell lung cancer
    Boni, C
    Zanelli, F
    ONCOLOGY, 2003, 65 : 50 - 54
  • [45] Treatment of non-small cell lung cancer
    Reinmuth, N.
    Heigener, D.
    Reck, M.
    INTERNIST, 2011, 52 (12): : 1414 - 1421
  • [46] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [47] Notch signaling and non-small cell lung cancer (Review)
    Zou, Bin
    Zhou, Xue-Liang
    Lai, Song-Qing
    Liu, Ji-Chun
    ONCOLOGY LETTERS, 2018, 15 (03) : 3415 - 3421
  • [48] The increasing role of amphiregulin in non-small cell lung cancer
    Busser, B.
    Coll, J. -L.
    Hurbin, A.
    PATHOLOGIE BIOLOGIE, 2009, 57 (7-8): : 511 - 512
  • [49] Targeted therapies in the treatment of non-small cell lung cancer
    De Greve, Jacques
    Decoster, Lore
    Van Meerbeek, Jan
    Vermeij, Joanna
    Teugels, Erik
    Schallier, Denis
    BULLETIN DU CANCER, 2008, 95 (03) : 358 - 364
  • [50] Antiangiogenic drugs in non-small cell lung cancer treatment
    Cascone, T
    Troiani, T
    Morelli, MP
    Gridelli, C
    Ciardiello, F
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (02) : 151 - 155